2023

1. Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)

   Actas Dermo-Sifiliograficas

2. Observational 24-week study to assess clinical response to upadacitinib posttrial in patients with moderate-to-severe atopic dermatitis

   JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 571-575

3. [Translated article] BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings

   Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T479-T487